Results
Of the 12,342 embryos analyzed, 4.3% (n=519) were exposed to a SSRI while the remaining were not 95. 7% (n=11,823) . Overall euploid rate was 60%, aneuploidy rate 36.1%, and 3.9% inconclusive reports from the PGS laboratory. A significant difference was found in AMH levels (3.7 vs 2.7, p<0.005), and in euploidy rates for Group E (>43 years) (1.3 ±0.7 vs 0.5 ±0.5, p=0.04). No other differences were found in ploidy and inconclusive rates between groups. Of the 2132 SET cycles analyzed, 4.7% (n=97) of the cycles patients were exposed to a SSRI while the remaining were not 95.3% (n=2035). No differences were observed in the total number of live birth rate (28.5% vs 25.7%), ongoing pregnancy rate (21.3% vs 16.4%), implantation rate (71.3% vs 70.1%), clinical pregnancy (58.2% vs 59.7%), loss rate (21.3% vs 27.8%) and multiple pregnancy rate (0.6% vs 0%) between cohorts.
Conclusions
SSRIs are the most widely prescribed category of antidepressants in women of reproductive age. Treatment of anxiety and depression are complicated, and the health of the mother must be balanced against any potential embryo toxic, teratogenic, or development risks to their offspring. This study did not identify a difference in implantation or ongoing pregnancy rates in patients exposed to SSRIs. The rate of embryo euploidy was similar among patient cohorts. The observance of a significant decrease in euploid embryos in patients >43 was consistent with the knownd age-related decline of embryo quality. Long-term clinical trials would help to fully define the risk/benefit ratio of SSRI exposure during ART treatment.
Support
None. 
